ELOX · Eloxx Pharmaceuticals, Inc.
$18.53
-0.76 (-3.94%)
At close · Aug 26
Going-concern doubt
— cleared Aug 11, 2026
The latest filing no longer states the doubt (first flagged May 5, 2026).
View the 10-Q filed Aug 11, 2026Market Cap
$77.86M
Shares
4.04M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
-100%
FY2025
Net Income
-$6M
-90.7%
FY2025
Operating Margin
-38.81%
FY2024
Diluted EPS
-$0.49
+41.7%
FY2025
Operating Cash Flow
-$6.33M
-34.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $0 | $6.36M | $0 | — | — | — | — | — | — | $182.23K | $182.23K | $182.23K | — | $200K | |
| — | $3.06M | $3.58M | $8.6M | $23.73M | $22.9M | $14.59M | $26.35M | $20.49M | $16.4M | $8.99M | $5.84M | $3.34M | $2.09M | $2.57M | |
| — | $3.38M | $5.25M | $8.69M | $10.69M | $20.45M | $14.85M | $24.21M | $26.48M | $2.7M | $854K | $442K | $3.68M | $2.5M | $2.72M | |
| — | — | — | — | — | — | — | — | — | — | $24.98K | $24.98K | $331.38K | $291.05K | $255.64K | |
| — | — | — | — | — | — | — | — | — | $44.08K | $93.39K | $177.07K | $349.66K | $293.63K | $258.02K | |
| — | — | — | — | — | — | $1.89M | — | — | — | — | — | — | — | — | |
| — | $6.44M | $8.83M | $17.29M | $34.42M | $66.02M | $33.46M | $50.56M | $47.57M | $20.39M | $9.84M | $6.28M | — | — | — | |
| $3.01M | — | — | — | — | — | — | — | — | $4.59M | $11.27M | $18.15M | $9.25M | $4.65M | $5.29M | |
| — | -$6.44M | -$2.47M | -$17.29M | -$34.42M | -$66.02M | -$33.46M | -$50.56M | -$47.57M | -$20.39M | -$9.84M | -$6.28M | -$9.15M | -$4.65M | -$5.09M | |
| — | — | -38.81% | — | — | — | — | — | — | — | — | — | -5019.95% | — | -2545.2% | |
| — | — | — | — | — | — | — | — | — | — | — | — | -$8.8M | -$4.36M | -$4.83M | |
| — | $27K | -$53K | $31K | -$1.65M | -$709K | -$1.12M | -$319K | $502K | -$824K | -$7000 | — | — | — | -$115.87K | |
| — | -$6M | -$3.14M | -$17.05M | -$36.07M | -$66.73M | -$34.58M | -$50.87M | -$47.06M | -$21.21M | -$9.85M | -$6.4M | — | — | — | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $122K | -$1.04M | -$680K | — | — | — | — | |
| — | -$6M | -$3.14M | -$17.05M | -$36.07M | -$66.73M | -$34.58M | -$50.87M | -$47.19M | -$21.21M | -$9.85M | -$6.41M | -$9.23M | -$6.12M | -$5.07M | |
| — | — | -49.43% | — | — | — | — | — | — | — | — | — | -5062.44% | — | -2533.07% | |
| -$6.63M | — | — | — | — | — | — | — | — | -$6.19M | -$8.45M | -$18.9M | -$13.85M | -$6.99M | -$6.69M | |
| — | — | — | — | — | -$66.73M | -$34.6M | -$50.86M | -$47.19M | -$23.62M | -$8.45M | -$18.9M | -$13.85M | -$6.99M | — | |
| USD/shares | — | -$0.49 | -$0.84 | -$6.63 | -$16.65 | -$38.15 | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$0.49 | -$0.84 | -$6.63 | -$16.65 | -$38.15 | — | — | — | — | — | — | — | — | — |
| shares | — | 12.35M | 3.76M | 2.57M | 2.17M | 1.75M | 40.12M | 38.06M | 32.44M | 4.98M | 4.21M | 4.15M | 5.48M | 136.64M | 85.7M |
| shares | — | 12.35M | 3.76M | 2.57M | 2.17M | 1.75M | 40.12M | 38.06M | 32.44M | 4.98M | 4.21M | 4.15M | 5.48M | 136.64M | 85.7M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2017–FY2019: $0 in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.33×
EV/EBIT
—
Peer median 12.10×
P/E (TTM)
—
Peer median 10.33×
Peer medians compare against the 299 similar-size Biotechnology companies (of 534 listed).